Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Gossamer Bio secures up to $250 million through a structured private placement to fund seralutinib through potential FDA approval. This includes $150 million of committed capital from institutional investors.
PUBLIC · GOSSAug 21, 2026•about 4 hours ago
Amount Raised
$250 Million
Round Type
Post-IPO Equity
San DiegoBiotechnologyTherapeuticsPharmaceuticalBiopharma
Description
Gossamer Bio has announced a securities purchase agreement with new and existing institutional investors for a private placement financing. The funding will be used to support the development of seralutinib for treating pulmonary arterial hypertension and other related conditions. The deal involves up to $250 million, with a significant portion already committed. This financing aims to carry the drug through its potential FDA approval.
Company Information
Company
Gossamer Bio
Location
3013 SCIENCE PARK
San Diego, California, United States
About
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
Don't miss Gossamer Bio's next move
Get an email the moment Gossamer Bio raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Verified contactsFaheem H., Executive Officer, Director hidden
Predictive Intelligence
Strategic
ML-powered predictions for Gossamer Bio's next move
San DiegoBiotechnologyTherapeuticsPharmaceuticalBiopharma